-
BioSante Pharmaceuticals Prices Public Offering of 16M Shares Common Stock at $3.00/Share
Thursday, July 28, 2011 - 9:02am | 157BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the pricing of its previously announced underwritten public offering of 16.0 million shares of its common stock, offered at a price of $3.00 per share to the public. The net proceeds to BioSante from this offering are expected to be...
-
FDA Agrees with Dynavax on Consistency of HEPLISAV Lots
Thursday, July 28, 2011 - 8:14am | 101Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration advised the company that "CBER agrees that clinical consistency of three consecutively manufactured lots of HEPLISAV has been demonstrated...
-
BYDUREON™ Reply Submitted to FDA
Thursday, July 28, 2011 - 8:02am | 362Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (...
-
Jefferies Lowers PT On Metabolix To $13
Thursday, July 28, 2011 - 6:47am | 26Jefferies & Company has lowered the price target on Metabolix (NASDAQ: MBLX) from $15 to $13 and maintains its Buy rating.
-
MLV Provides Color on Affymax
Thursday, July 28, 2011 - 3:36am | 113MLV provided color on Affymax (NASDAQ: AFFY). In a research report published today, the rating agency commented on the company's new drug peginesatide. In the report, MLV states, “This morning, Affymax and its partner Takeda (TSE: 4502; Not Covered) announced the NDA acceptance by the FDA for...
-
Rodman & Renshaw Reiterates Market Outperform and PT of $3 on AEterna Zentaris
Thursday, July 28, 2011 - 3:12am | 60Rodman & Renshaw reiterated its Market Outperform rating on AEterna Zentaris (NASDAQ: AEZS). At the same time, the rating agency left its price target on the company's stock unchanged at $3. On Wednesday, AEZS lost 2.83% of its value to finish the day at $2. Its shares rebounded in today's pre-...
-
Stocks to Watch for Thursday 7/28/2011: Fresh 52 Week Highs and Lows
Thursday, July 28, 2011 - 2:37am | 3403Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and entry/exit points become more clearly defined. The following stocks hit new 52-week highs in Wednesday's trading session (listed from highest total volume to...
-
Wednesday's S&P 500 Sector Recap: Hottest and Coldest Sectors
Wednesday, July 27, 2011 - 5:36pm | 1734The S&P 500 (SPX) took a major hit in Wednesday's trading session, finishing down 27.05 points, or 2.03%, from Tuesday's close to 1304.89. The selling began just after the opening bell, and the index extended its losses throughout the session, closing near the low of the day (1303.49), as...
-
Biotech Stocks to Watch for Thursday
Wednesday, July 27, 2011 - 5:31pm | 3093( click to enlarge ) MELA Sciences, Inc. (NASDAQ:MELA) had a great move on the upside today and closed at $2.67. The stock is setting up to break out and has one more level to go, which is $2.72. MELA Sciences is a well capitalized company, with $1.03 in cash per share. This stock has a...
-
BioSante Pharmaceuticals Announces Proposed Public Offering of Common Stock
Wednesday, July 27, 2011 - 4:42pm | 103BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering will be sold by BioSante. The offering is subject to market conditions, and there can be no assurance as...
-
Check Out The Chart: An Unhealthy Biotech ETF?
Wednesday, July 27, 2011 - 1:52pm | 324Health care and biotech ETFs had been providing some noteworthy shelter from the various trials and tribulations faced by the market this year, but headwinds provided by the debt ceiling debate are proving that no ETF is immune from the tom foolery politicians engage in. Such is life for the First...
-
UPDATE: JP Morgan Raises PT on Gilead Sciences from $45 to $50
Wednesday, July 27, 2011 - 9:53am | 126J.P. Morgan has published a research report on Gilead Sciences (NASDAQ: GILD) raising the price target. In the report, J.P. Morgan wrote, "Gilead reported solid 2Q results with non-GAAP EPS of $1.00, ahead of JPMe/cons estimates of $0.99 with total product revenues growing 11% y/y to $2.04B (cons...
-
Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Wednesday, July 27, 2011 - 9:02am | 183Marshall Edwards, Inc.(Nasdaq: MSHL) announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company's investigational compound and lead mitochondrial inhibitor drug candidate, NV-344...
-
CytRx Prices $20.4 Million Public Offering of 39.2M Shares at $0.52/Share
Wednesday, July 27, 2011 - 8:46am | 229CytRx Corporation (Nasdaq: CYTR) today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase up to 39,200,000 shares of common stock at a combined public offering price of $0.52 per share and related warrant for gross proceeds of...
-
Oppenheimer Price Target and Rating Updates 7/27/11
Wednesday, July 27, 2011 - 8:41am | 287Oppenheimer made a number of price target and rating updates in a research report published today. Amazon (NASDAQ: AMZN) had its rating reiterated at Outperform. At the same time, its price target was raised from $220 to $250. On Tuesday, AMZN closed the day at $214.18. Its shares added 5.66% to...